Dr. Reddy?s Laboratories Ltd. announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK). Dr. Reddy?s Versavo® is a (bevacizumab) biosimilar of Avastin® and indicated for the treatment of several types of cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer and metastatic breast cancer. Versavo® is the first Dr. Reddy?s biosimilar product to be approved and launched in the UK.

It is available in strengths of 100mg and 400mg single use vials. Dr. Reddy?s launched Versavo® in India in 2019. Subsequently, Versavo® was introduced in other markets such as Thailand, Ukraine, Nepal, and Jamaica under the same brand name.

In Colombia, the product was launched under the brand name Persivia®.